Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: maravai.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 11/8/2024 | Outperform → Mkt Perform | William Blair | |
| 8/28/2024 | $10.00 | Overweight | Wells Fargo |
| 8/13/2024 | $11.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/10/2024 | $15.00 | Buy | Craig Hallum |
| 12/12/2023 | $10.00 → $8.00 | Neutral → Buy | BofA Securities |
| 8/8/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/23/2023 | $18.00 → $14.00 | Outperform → Neutral | Credit Suisse |
| 5/9/2023 | Buy → Neutral | Goldman | |
| 1/5/2023 | $20.00 → $16.00 | Buy → Neutral | UBS |
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
Wolfe Research initiated coverage of Maravai Life Sciences with a rating of Peer Perform
William Blair downgraded Maravai Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Maravai Life Sciences with a rating of Overweight and set a new price target of $10.00
Morgan Stanley downgraded Maravai Life Sciences from Overweight to Equal-Weight and set a new price target of $10.00 from $11.00 previously
Craig Hallum initiated coverage of Maravai Life Sciences with a rating of Buy and set a new price target of $15.00
BofA Securities upgraded Maravai Life Sciences from Neutral to Buy and set a new price target of $8.00 from $10.00 previously
KeyBanc Capital Markets downgraded Maravai Life Sciences from Overweight to Sector Weight
Credit Suisse downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $14.00 from $18.00 previously
Goldman downgraded Maravai Life Sciences from Buy to Neutral
UBS downgraded Maravai Life Sciences from Buy to Neutral and set a new price target of $16.00 from $20.00 previously
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $65.2 million, Net loss of $(176.0) million (including a goodwill impairment of $154.2 million), and Adjusted EBITDA of $12.7 million; andUpdated revenue guidance for the full year 2024 to be in the r
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $73.4 million, Net loss of $(14.5) million, and Adjusted EBITDA of $16.9 million; andReaffirmed revenue guidance for the full year 2024 in the range of $265.0 million to $285.0 million. Partnerships and Innovation: TriLink BioTechnologies announced a collaboration with the John Hopkins University aimed at accelerating transformationa
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4292675. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $64.2 million, Net loss of $(22.7) million, and Adjusted EBITDA of $7.8 million; andReaffirmed financial guidance for the full year 2024 including a revenue range of $265.0 million to $285.0 million. Partnerships and Innovation: TriLink BioTechnologies and Lonza entered into a Non-exclusive License and
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 6629752. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety data from First-In-Human Phase 1 trial Executed a term sheet to utilize our microbial protein production platforms to develop production strains for the production of recombinant serum albumin initiall
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2023, together with other business updates. Recent highlights include: Financial: Quarterly revenue of $74.1 million, Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets, and Adjusted EBITDA margin of 28%;Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%; andIntroduced full year 2024 revenue guidance range of $
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4939675. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https:
Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2023, together with other business updates. Recent highlights include: Financial: Quarterly revenue of $66.9 million, Net loss of $(15.1) million, and Adjusted EBITDA margin of 18%; andUpdated financial guidance
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William "Trey" Martin, III has been appointed to the Company's Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin's commitment to innovation, leadership capabilities, and deep industry knowledge. "We are thrilled to welcome Trey to our Board of Directors," said Carl Hull, Maravai's co-founder and Executive Chair of its Board of Directors. "Trey's extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective
William "Trey" Martin, III assumes the role of Maravai's CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William "Trey" Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company's previously announced CEO succession plan. Carl Hull, Maravai's co-founder and prior interim CEO, will continue to serve as Maravai's Executive Chairman of the Board. "We are thri
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert ("Chip") Hance has stepped down from the Company's Board of Directors (the "Board") effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20, 2023. Mr. Hance, a 25-year veteran in the medical device industry, is set to become the Chairman of the Board of the Medical Device Innovation Consortium (MDIC) and stepped down from the Board in anticipation of the increased time commitment associated with that role. D
Maravai announces plans for William "Trey" Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai's CEO in July 2023 Carl Hull to continue to serve as Executive Chairman and Interim CEO SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced plans for William "Trey" Martin, III to serve as President of Maravai's Biologics Safety Testing Segment beginning December 5, 2022, and expects that Martin will assume the role of Chief Executive Officer of Maravai LifeSciences on Ju
William "Trey" Martin, III appointed to succeed Carl Hull as Chief Executive OfficerHull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that its Board of Directors has appointed William "Trey" Martin, III as its chief executive officer (CEO). Mr. Martin comes to Maravai most recently from Danaher Corporation, where he was the Senior Vice President of New Business, Genomic Medicine. Maravai's first CEO and co-founder Carl Hull will directly support Mr. Martin during this leadership tra
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights' Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplished industry veteran, and we are thrilled to welcome her to our Board," said Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights. "With more than two decades of medical device, biotech and pharmaceutical experience, Dr. Hopfield brings to Berkeley Lights valuable strategic insight and a strong focus on performance to drive our unrivaled ability to understand c
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in a fireside chat at the Stifel Healthcare Conference in New York, NY. On November 21, 2024, at 2:00 a.m. PST/ 9:00 a.m. GMT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare C
Officinae Bio's breakthroughs in AI-enabled methodologies for nucleic manufacturing to enhance Maravai's mRNA manufacturing capabilities within the TriLink BioTechnologies business Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support t
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $65.2 million, Net loss of $(176.0) million (including a goodwill impairment of $154.2 million), and Adjusted EBITDA of $12.7 million; andUpdated revenue guidance for the full year 2024 to be in the r
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or integrity TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics. CleanScribe RNA Polymerase is a novel DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. During the IVT reaction, dsRN
Cygnus' AccuRes Kits to recover, amplify, & quantify remaining host cell DNA during biologic drug manufacturing to produce safer, more stable vaccines, therapies, and more Cygnus Technologies (Cygnus), TriLink BioTechnologies (TriLink®), both part of Maravai LifeSciences (NASDAQ:MRVI) have collaborated to launch Cygnus' AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an assay with unparalleled sensitivity and specificity to help produce safer, more stable biotherapeutics that surpass regulatory standards. This press release features multimedia. View the full release here: https://www.businesswire.com
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September. On August 14, 2024, at 11:00 a.m. PDT/ 2:00 p.m. EDT, Trey Martin, Chief Executive Officer, will participate in a panel discussion of the Critical Components of the Genomic Medicine Supply Chain at the UBS Genomic Medicine Conference in Dana Point, CA. On September 4, 2024, at 6:30 a.m. PDT/ 9:30 a.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $73.4 million, Net loss of $(14.5) million, and Adjusted EBITDA of $16.9 million; andReaffirmed revenue guidance for the full year 2024 in the range of $265.0 million to $285.0 million. Partnerships and Innovation: TriLink BioTechnologies announced a collaboration with the John Hopkins University aimed at accelerating transformationa
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William "Trey" Martin, III has been appointed to the Company's Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin's commitment to innovation, leadership capabilities, and deep industry knowledge. "We are thrilled to welcome Trey to our Board of Directors," said Carl Hull, Maravai's co-founder and Executive Chair of its Board of Directors. "Trey's extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4292675. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and lowers the price target from $8 to $7.
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
Gainers Innovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million. Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 53.94% to $0.32. The company's market cap stands at $7.5 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 34.56% to $0.27. The company's market cap stands at $4.2 million. Apollomics (NASDAQ:APLM) shares increased by 28.89% to $0.34. The market value of their outstanding shares is at $36.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 25.07% to $0.2. The market value of their outstanding shares is at $4.5 million. Chromocell Therapeuti
4 analysts have expressed a variety of opinions on Maravai LifeSciences (NASDAQ:MRVI) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.25, with a high estimate of $15.00 and a low estimate of $10.00. This upward tren
Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and raises the price target from $8 to $10.
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 166.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $64.179 million which beat the analyst consensus estimate of $60.548 million by 6.00 percent. This is a 18.79 percent decrease over sales of $79.025 million the same period last year.
10-Q - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
10-Q - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
10-Q - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
ARS - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)